Market Intelligence, Emerging Biology, Clinical Progress, and High-Purity Reagents for TREX-2 Complex & mRNA Export Targeting.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PCID2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PCID2 Full-Length & Domain Truncation Recombinant Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 / E. coli dual expression. | View PCID2 Products |
| Gene Delivery | PCID2 Promise-ORF / Lentivirus. Full-length ORF for stable overexpression cell lines. | View PCID2 Products |
| Benchmark Ab | Anti-PCID2 Recombinant Rabbit mAb. Research-grade positive control for Western blot and immunoprecipitation. | View PCID2 Products |
| Validator | PCID2 siRNA Set. Predesigned panel for knockdown verification. | View PCID2 Products |
| Related Target A | GANP (MCM3AP). Core TREX-2 complex partner; essential for mRNA export channel assembly. | View GANP Products |
| Related Target B | DSS1. TREX-2 scaffolding component; synergistic dependency in CRISPR screens. | View DSS1 Products |
| Related Target C | XPO1 (CRM1). Canonical mRNA export receptor; comparative pathway and resistance bypass analysis. | View XPO1 Products |
| Related Target D | BRCA1. Putative interacting partner in synthetic lethality and DNA repair pathways. | View BRCA1 Products |
| Related Target E | ENY2. Putative structural partner within the TREX-2 transcription and export complex. | View ENY2 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular localization limits membrane-based assays | Full-length soluble protein (>95% purity, endotoxin <1 EU/µg) suitable for SPR, ITC, and fluorescence polarization. |
| TREX-2 multiprotein assembly validation | Co-purification compatible tags; multi-expression systems (E. coli and HEK293) for binary and ternary complex reconstitution. |
| Lack of functional knockdown controls | Predesigned siRNA set for specificity verification in cellular mRNA export and essentiality assays. |
| Off-target effects in mRNA export pathway | Ortholog and paralog panels (GANP, DSS1, XPO1) for rigorous counter-screening. |
| Evaluating Protein-Protein Interactions (PPIs) | High-purity Recombinant PCID2 proteins (>95%) strictly verified by mass spectrometry for binding assays (SPR/BLI). |
| PROTAC Degradation Validation | Sequence Confirmed Lentivirus for constructing stable intracellular assay cell lines. |
| False Positives in Knockdown Assays | Validated siRNA included for specificity checks and pathway confirmation. |
Live PCID2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
PCID2 remains an emerging target anchored in preclinical oncology and fundamental mRNA export biology. As a core scaffolding component of the TREX-2 complex, PCID2 has surfaced in CRISPR essentiality screens across solid tumor models. The current discovery landscape is dominated by academic mechanistic studies and early-stage biotech exploration of protein-protein interaction disruptors and molecular glues. No molecules have reached Phase I, positioning PCID2 as a next-wave intracellular target. The race for PCID2 therapeutics is intensifying as researchers uncover its critical role in the TREX-2 complex, mRNA nuclear export, and centrosome regulation. While traditionally considered an "undruggable" intracellular scaffold protein, major players are shifting focus from traditional modalities to Targeted Protein Degradation (PROTACs) and small molecule PPI inhibitors. As the understanding of PCID2's dependency in aggressive B-cell lymphomas and BRCA1-mutant tumors deepens, the next wave of R&D is targeting synthetic lethality paradigms and targeted ubiquitin-mediated degradation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTACs | Early-stage Biotech | Solid Tumors / B-Cell Lymphomas | Degradation Assay (Need Lentivirus for Stable Cell Line generation) |
| Small Molecule (PPI Inhibitor) | Academic / Discovery | Refractory Cancers | Selectivity Assay (Need High-Purity Recombinant Proteins for SPR) |
| siRNA / Gene Therapy | Preclinical Pipelines | Hematological Malignancies | Knockdown Verification (Need Sequence Verified siRNA Sets) |
Future Directions & Synthetic Lethality Strategy
Emerging preclinical evidence indicates that PCID2 dependency in certain cancer subtypes (e.g., BRCA1-mutant breast/ovarian cancers) may create synthetic lethality opportunities. Combinations with PARP inhibitors or other DDR pathway inhibitors are under active investigation. The convergence of PROTAC technology and intracellular delivery advances is expected to accelerate PCID2-directed pipelines toward IND filing within the next 3–5 years.